JMP Securities Sticks to Its Buy Rating for PolyPid (PYPD)

JMP Securities analyst Roy Buchanan reiterated a Buy rating on PolyPid (PYPDResearch Report) today and set a price target of $3.00. The company’s shares opened today at $1.09.

Buchanan covers the Healthcare sector, focusing on stocks such as PolyPid, Arbutus Biopharma, and Enanta Pharmaceuticals. According to TipRanks, Buchanan has an average return of -27.1% and a 19.54% success rate on recommended stocks.

Currently, the analyst consensus on PolyPid is a Strong Buy with an average price target of $8.63.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $8.57 and a one-year low of $1.03. Currently, PolyPid has an average volume of 927.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company’s proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.

Read More on PYPD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More